Q&A: Carlyle sees rise in Japanese carve-outs

The Carlyle Group sees a rise in Japanese companies willing to say goodbye to non-core businesses in order to boost their return on equity and compete more effectively on the global stage.  Private equity firms have long aspired to buy large, under-managed units of marquee Japanese companies, and there is an unusually large crop of carve-outs this year. Japan’s biggest drugmaker Takeda Pharmaceutical is spinning out Wako Pure Chemicals; Nissan Motors is auctioning autoparts make…